“MOVEdiabetes” a trial to promote physical activity for adults with type 2 diabetes in primary health care in Oman

Conditions

Type 2 diabetes Nutritional, Metabolic, Endocrine

Thamra S. Alghafri, Saud M. Al Harthi, Fatma Al-Ajmi, Yahya Al‐Farsi, Angela M. Craigie et al. (7 authors)

BMC Public Health2020-06-0820 citations

Study protocol for “MOVEdiabetes”: a trial to promote physical activity for adults with type 2 diabetes in primary health care in Oman

Thamra S. Alghafri, Saud M. Al-Harthi, Yahya Al‐Farsi, Angela M. Craigie, Maureen Mcleod et al. (6 authors)

BMC Public Health2017-01-0611 citations

10.1186/s12889-016-3990-0

Interventions

1. The Intervention Group (IG) will receive the “MOVEdiabetes” personalised three PA consultations (baseline, 2nd month and 3rd months), pedometer (YAMAX Digi-walker SW-200) to supervise the weekly st

(b) self-monitoring to achieve these goals

(c) frequent contact to provide accountability and sustain focus

(d) use of problem-solving and other “toolbox” strategies to address goals and potential barriers to achieving them

and (e) emphasis on managing individual high-risk situations. Based on these techniques, various intervention components were chosen to offer flexibility

to adjust to individual differences and preferences and to strengthen change. The approach will take particular care to emphasise the importance of regular (weekly) step count recordings through the p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adults aged 18 to 60 years 2. Diagnosed with type 2 diabetes 3. Attending HC for at least six months previously for follow up 4. Assessed by research officer as having inactive behaviour using a structured screening questionnaire designed for this project. 5. No contraindication to physical activity 6. Able to speak and read Arabic 7. Willing and able to consent to the study

Exclusion criteria

Exclusion criteria: 1. Patients with Type 1 diabetes 2. Patients with a history of myocardial infarction in the previous 6 months 3. Patients with a serum creatinine >140 mmol/L (from previous readings –Alshifa system). 4. Patients with diabetic foot ulcers or at high risk of ulcer (severe peripheral neuropathy) 5. Insulin usage 6. Repeated hypoglycaemia or sever hypoglycaemia in previous 12 months 7. No internet access for WhatsApp

Design outcomes

Primary

Measure	Time frame
Change in physical activity levels measured by changes in MET-min/week reported by participants using the Global physical activity questionnaire (GPAQ) and validated objectively by activPAL accelerometers at baseline, 3 months and 12 months	—

Secondary

Measure	Time frame
1. Changes in metabolic and cardiovascular biomarkers (BMI, waist circumference, BP, HbA1c and lipids) recorded from the health information system in the health centre at baseline, 3 months and 12 months 2. General health, self-efficacy and social support, evaulated by questionnaire at baseline and 3 months 3. Perceived acceptability of the programme and intervention cost description assessed at 12 months	—

Measure

Time frame

1. Changes in metabolic and cardiovascular biomarkers (BMI, waist circumference, BP, HbA1c and lipids) recorded from the health information system in the health centre at baseline, 3 months and 12 months 2. General health, self-efficacy and social support, evaulated by questionnaire at baseline and 3 months 3. Perceived acceptability of the programme and intervention cost description assessed at 12 months

—

Countries

Oman

Outcome results

None listed